Non-representative sampling detected during internal audit – inspection-ready sampling justification


Published on 26/04/2026

Investigation of Non-representative Sampling Findings During Internal Audits

Non-representative sampling detected during an internal audit presents a serious challenge for pharmaceutical manufacturers and quality control professionals. It can lead to significant implications on product quality, regulatory compliance, and ultimately, patient safety. In this article, we will explore how to effectively investigate such instances, collect pivotal data, and implement corrective and preventive actions.

By the end of this article, you will be equipped to recognize symptoms of non-representative sampling, identify likely causes, and establish an effective investigation workflow. This guide aims to enable you to resolve sampling discrepancies efficiently and maintain inspection readiness by implementing robust control strategies.

Symptoms/Signals on the Floor or in the Lab

Identifying symptoms is the first step in addressing non-representative sampling. Common signals that may alert staff to an issue include:

  • Inconsistent test results: Variability in results from multiple tests of a single batch can signal potential sampling issues.
  • Vendor complaints: Feedback from vendors regarding discrepancies in expected quantities or conditions can indicate poor sampling
practices.
  • Audit findings: Observations made during internal audits highlighting inadequate sampling methods or conditions.
  • Material discrepancies: Differences in the reported quality of raw materials from various sources raise concerns about sampling techniques.
  • When these symptoms arise, it is critical to respond swiftly to uncover the root cause and mitigate the impact on production and compliance.

    Likely Causes (by category: Materials, Method, Machine, Man, Measurement, Environment)

    Upon observing potential non-representative sampling, investigating its root causes should follow a structured approach, assessing various categories of influences:

    1. Materials

    • Variability in raw materials from suppliers can result in inconsistent sampling.
    • Substandard storage conditions may lead to degradation of materials, affecting test results.

    2. Method

    • Ineffective sampling techniques or improper use of tools can yield non-representative samples.
    • Failure to follow established Standard Operating Procedures (SOPs).

    3. Machine

    • Malfunctioning equipment used for sampling can result in inaccurate quantities.
    • Calibration issues can cause measurement errors, leading to misleading results.

    4. Man

    • Inadequate training of personnel responsible for sampling increases risk of errors.
    • Failures in communication among team members regarding sampling protocols are detrimental.

    5. Measurement

    • Improper analytical methods can lead to sample mischaracterization.
    • Changes in measurement tools over time can affect reliability and accuracy.

    6. Environment

    • Environmental factors such as humidity, temperature, and contamination can alter sample integrity.
    • Poorly controlled or monitored storage facilities can lead to deviations in shelf life or quality.

    Understanding these potential categories aids in narrowing down investigation pathways effectively.

    Immediate Containment Actions (first 60 minutes)

    In the initial stages following detection of non-representative sampling, impose immediate containment actions. This may include:

    • Isolate affected materials: Quarantine any material batches suspected of being sampled incorrectly to prevent further processing.
    • Notify relevant personnel: Inform Quality Assurance, Quality Control, and other relevant team members of the issue.
    • Document the situation: Record details of the sampling findings, symptoms observed, and any immediate actions taken.
    • Conduct a preliminary impact assessment: Evaluate the potential impact on production, release, and compliance.

    These immediate actions serve to limit the effects of the non-representative sampling while formulating a comprehensive investigation plan.

    Investigation Workflow (data to collect + how to interpret)

    An effective investigation workflow should involve collecting and analyzing various types of data to unravel the issue:

    Data Collection:

    • Sampling records and logs to identify discrepancies.
    • Analytical test results from batches affected by the suspect sampling.
    • Logs pertaining to environmental monitoring (temperature/humidity) and equipment maintenance.
    • Employee training records related to sampling procedures.

    Data Interpretation:

    • Compare the collected data against historical trends to identify anomalies.
    • Examine potential links between sampling processes and downstream quality metrics.
    • Utilize visual aids, like control charts, to illustrate variations and trends in the sampling results.

    Establishing connections between collected data and observed symptoms is crucial for directing further investigation efforts.

    Root Cause Tools (5-Why, Fishbone, Fault Tree) and when to use which

    Utilizing structured root cause analysis tools helps ensure a thorough understanding of the underlying issues:

    1. 5-Why Analysis

    This method involves asking “why” multiple times (typically five) to delve deeper into the root of the problem. It is best suited for simple issues with a clear line of questioning.

    2. Fishbone Diagram

    Also known as the Ishikawa diagram, this tool provides a visual representation of factors contributing to the problem categorized by Materials, Methods, Machines, Man, Measurement, and Environment. It’s ideal for complex issues where multiple potential causes may be at play.

    3. Fault Tree Analysis

    This deductive approach begins with a top-level failure and works down through potential causes. It’s particularly effective for identifying failures in systems or processes with complex interdependencies.

    Selecting the appropriate tool depends on the complexity of the case and the resources available for conducting the analysis.

    CAPA Strategy (correction, corrective action, preventive action)

    Implementing a robust CAPA strategy is critical following investigations:

    1. Correction

    Immediate steps taken to rectify the existing issue, such as re-evaluating the affected batches of raw materials or re-sampling using proper techniques.

    2. Corrective Action

    Actions taken to prevent recurrence, such as establishing stricter sampling protocols or enhanced training programs for personnel.

    Related Reads

    3. Preventive Action

    Long-term strategies to mitigate future incidents, which might include ongoing vendor qualifications, routine audits, and continuous improvement processes.

    Documenting all steps within the CAPA framework is crucial for compliance and for future reference during regulatory inspections.

    Control Strategy & Monitoring (SPC/trending, sampling, alarms, verification)

    Establishing a control strategy post-investigation ensures that measures are implemented effectively:

    • Statistical Process Control (SPC): Utilize control charts to continuously monitor the consistency of sampling processes.
    • Trending Analyses: Regularly review data trends regarding sampling methods and material testing to catch emerging issues early.
    • Alarm Systems: Implement alerts for out-of-specification results or deviations from standard sampling procedures.
    • Verification: Conduct periodic verification of sample handling and testing processes to ensure compliance with established protocols.

    A well-defined control strategy fosters an environment of quality assurance and promotes consistent compliance with GMP standards.

    Validation / Re-qualification / Change Control impact (when needed)

    Based on findings, specific validation or re-qualification activities may become necessary:

    • Validation: Any alterations to sampling methodologies or equipment must be validated to ensure they yield reliable and reproducible results.
    • Re-qualification: If new equipment is introduced, or significant changes are made, re-qualification is essential to validate performance against specified requirements.
    • Change Control: Adhere to change control procedures to document all amendments made in response to the investigation findings, ensuring robust traceability.

    These activities are fundamental to maintaining regulatory compliance and ensuring continuous product quality throughout the lifecycle of materials.

    Inspection Readiness: what evidence to show (records, logs, batch docs, deviations)

    Maintaining inspection readiness is crucial following such investigations:

    • Records: Ensure all records related to the sampling process are updated and readily accessible, including training records and calibration logs.
    • Logs: Consistently update environmental monitoring logs and equipment maintenance records to reflect ongoing compliance.
    • Batch Documentation: Review batch records to confirm adherence to specifications and SOPs throughout the sampling process.
    • Deviations: Document any deviations associated with the non-representative sampling thoroughly to present a clear narrative during inspections.

    Providing thorough documentation not only ensures compliance but also fosters a culture of accountability and continuous improvement.

    FAQs

    What is non-representative sampling?

    Non-representative sampling occurs when the sample collected does not accurately reflect the entire batch, leading to potential quality discrepancies.

    Why is representative sampling important in pharmaceutical manufacturing?

    Representative sampling ensures that the analyzed samples provide an accurate picture of the batch quality, which is essential for maintaining product safety and regulatory compliance.

    What are the immediate steps to take after detecting sampling issues?

    Immediate steps include isolating the affected material, notifying relevant personnel, documenting the issue, and assessing the potential impact.

    What tools are effective in root cause analysis for non-representative sampling?

    Effective tools include the 5-Why Analysis, Fishbone Diagram, and Fault Tree Analysis, each serving different complexity levels in investigation.

    What is the purpose of a CAPA strategy?

    A CAPA strategy aims to correct the issue, implement corrective actions to prevent recurrence, and establish preventive measures for long-term compliance.

    How does a control strategy aid in preventing sampling errors?

    A control strategy involves continuous monitoring and verification of sample collection methods to identify variations early and maintain compliance.

    When should validation or re-qualification occur?

    Validation or re-qualification should occur when changes are made to sampling methods, equipment, or processes that impact material quality.

    What documentation is essential for inspection readiness regarding sampling processes?

    Essential documentation includes records of the sampling process, training logs, maintenance and calibration logs, and batch documentation on deviations.

    How can environmental conditions impact sample integrity?

    Poorly controlled environmental conditions (humidity, temperature) may lead to material degradation, compromising sample integrity and reliability.

    What role does employee training play in ensuring proper sampling?

    Employee training ensures that personnel are knowledgeable about correct sampling techniques and procedures to reduce the risk of errors and non-representative samples.

    How often should vendors be audited to ensure quality materials?

    Vendor audits should be conducted regularly based on risk assessment results, historical performance, and regulatory expectations to ensure ongoing compliance.

    Can non-representative sampling impact product shelf life?

    Yes, inaccurate sampling can lead to erroneous shelf-life assessments and affect overall product quality, regulatory compliance, and safety.

    Pharma Tip:  Sampling plan not risk-based during internal audit – CAPA to prevent recurrence